Home > Insider Trading > Filing (0001209191-20-015670)

Filing Details

Accession Number:: 0001209191-20-015670
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-03 19:03:43
Reporting Period:: 2020-03-03

Accepted Time:: 2020-03-03 19:03:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787297	Passage Bio Inc.	PASG	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1619294	Thomas Woiwode	One Sansome Street, Suite 3630 San Francisco CA 94104	Yes	No	Yes	No
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1765253	Versant Vantage I, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777651	Versant Vantage I Gp, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777652	Versant Ventures Vi Gp-Gp, Llc	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777653	Versant Vantage I Gp-Gp, Llc	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1777654	Versant Ventures Vi Gp, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-03	2,977,242	$0.00	2,977,242	No	4	C	Direct
Common Stock	Acquisiton	2020-03-03	1,049,175	$0.00	4,026,417	No	4	C	Direct
Common Stock	Acquisiton	2020-03-03	708,352	$0.00	708,352	No	4	C	Indirect	By Versant Vantage I, L.P.
Common Stock	Acquisiton	2020-03-03	225,000	$18.00	933,352	No	4	P	Indirect	By Versant Vantage I, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect	By Versant Vantage I, L.P.
No	4	P	Indirect	By Versant Vantage I, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2020-03-03	2,977,242	$0.00	2,977,242	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2020-03-03	1,049,175	$0.00	1,049,175	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-03-03	708,352	$0.00	708,352	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect

Footnotes

Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Clare Ozawa, Robin L. Praeger and Tom Woiwode Ph.D., as managing members of VV VI GP-GP, may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer.
These securities are held of record by by Versant Vantage I, L.P. ("VV I"). Versant Vantage I, GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I, GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of Bradley J. Bolzon, Jerel C. Davis, Clare Ozawa, Robin L. Praeger and Thomas Woiwode Ph.D., as managing members of VV I GP-GP, may be deemed to share voting and dispositive power over the shares held by VV I and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer.